Skip to main content
Top
Gepubliceerd in:

23-03-2020

Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis

Auteurs: Ami Vyas, Ghadah Alghaith, Meghan Hufstader-Gabriel

Gepubliceerd in: Quality of Life Research | Uitgave 8/2020

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Cancer survivors that use multiple psychotropic medications are at an increased risk of psychotropic polypharmacy. We examined the association between psychotropic polypharmacy and health-related quality of life (HRQoL) among cancer survivors living in the USA.

Methods

We used the Medical Expenditure Panel Survey (MEPS) data for 2010, 2012, and 2014 to identify adult cancer survivors. Psychotropic polypharmacy was defined as use of at least two classes of psychotropic prescription medications. The physical component summary (PCS) and the mental component summary (MCS) were obtained from the 12-item Short Form Health Survey version 2 to measure HRQoL. Adjusted ordinary least square regressions were performed to evaluate the association between psychotropic polypharmacy and HRQoL.

Results

Among 31 million US cancer survivors (weighted from a sample of 2609), 16.3% reported psychotropic polypharmacy. Lung cancer survivors had the highest prevalence of psychotropic polypharmacy (22.5%), followed by survivors of breast cancer (17.8%), colorectal, and other gastrointestinal cancers (16.0%). The unadjusted PCS and MCS scores for those with psychotropic polypharmacy were significantly lower than those without psychotropic polypharmacy, overall, and for each cancer type. In multivariable regressions, cancer survivors with psychotropic polypharmacy had significantly lower PCS scores (β =  − 3.63, p < 0.0001) and MCS scores (β =  − 2.28, p = 0.0138) compared to those without psychotropic polypharmacy.

Conclusion

Cancer survivors requiring multiple psychotropic medications have poorer quality of life.
Bijlagen
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis
Auteurs
Ami Vyas
Ghadah Alghaith
Meghan Hufstader-Gabriel
Publicatiedatum
23-03-2020
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 8/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02478-6